For decades, COPD was treated as a single, uniform disease. That's changing. A new generation of targeted therapies is making it possible to match treatment to patient biology, and the results from recent clinical trials are giving clinicians reason for optimism.In this episode, Dr. MeiLan Han explores what biologics actually do in the context of COPD, how blood eosinophil levels guide patient selection, and what the BOREAS and NOTUS trials tell us about real-world outcomes. She also addresses the practical challenges of integrating biologics into clinical practice, from interpreting biomarker variability to setting honest expectations with patients.Learn more about this episode: http://chroniclungdiseases.com/en/copd-biologics-era-precision-medicineRESPIPLUS™ received support from Sanofi to develop an informative podcast series specifically tailored to COPD Biologics.Subscribe to The eXpand Podcast: • YouTube: https://bit.ly/eXpandPodcastYouTube• Apple Podcast: https://bit.ly/eXpandPodcastApple• Spotify: https://bit.ly/eXpandPodcastSpotify• Google Podcasts: https://bit.ly/eXpandPodcastGoogle#theexpandpodcast #copdbiologicsCOPD biologics, biologic therapy COPD, dupilumab COPD, COPD treatment, eosinophils COPD, COPD exacerbations, precision medicine COPD, targeted COPD therapy, COPD clinical practice, COPD biomarkers, COPD management, respiratory health, chronic lung disease, COPD physician guide, pulmonary medicine, MPOC biologiques, traitement MPOC, médecine de précision